{'fraction_non_alphanumeric': 0.05092592592592592, 'fraction_numerical': 0.021604938271604937, 'mean_word_length': 6.546511627906977, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Glucagon‐like peptide‐1(9‐36)amide metabolite inhibits weight gain and attenuates diabetes and hepatic steatosis in diet‐induced obese mice

Aims: The metabolic syndrome, a disease arising from the world‐wide epidemic of obesity, is manifested as severe insulin resistance, hyperlipidaemia, hepatic steatosis and diabetes. Previously we reported that GLP‐1(9‐36)amide, derived from the gluco‐incretin hormone, glucagon‐like peptide‐1 (GLP‐1), suppresses gluconeogenesis in isolated hepatocytes. The aims of this study were to determine the effects of GLP‐1(9‐36)amide in diet‐induced obese mice that model the development of the metabolic syndrome.